EAM
AIMT

Eagle Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Eagle Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,035,885
Closed -$21.6M – 686
2019
Q2 		$21.6M Sell
1,035,885
-291,048
-22% -$5.99M 0.11% 228
2019
Q1 		$29.7M Buy
1,326,933
+10,579
+0.8% +$249K 0.16% 208
2018
Q4 		$31.5M Sell
1,316,354
-19,403
-1% -$502K 0.2% 192
2018
Q3 		$36.4M Sell
1,335,757
-11,297
-0.8% -$320K 0.18% 197
2018
Q2 		$36.2M Sell
1,347,054
-53,428
-4% -$1.64M 0.2% 188
2018
Q1 		$44.6M Sell
1,400,482
-593,191
-30% -$20.9M 0.24% 149
2017
Q4 		$75.2M Sell
1,993,673
-248,618
-11% -$8.02M 0.41% 78
2017
Q3 		$56.4M Sell
2,242,291
-27,869
-1% -$601K 0.32% 106
2017
Q2 		$46.7M Buy
2,270,160
+135,374
+6% +$2.58M 0.28% 130
2017
Q1 		$46.4M Sell
2,134,786
-12,365
-0.6% -$254K 0.29% 106
2016
Q4 		$43.9M Buy
2,147,151
+11,061
+0.5% +$226K 0.29% 113
2016
Q3 		$32M Buy
2,136,090
+147,656
+7% +$1.99M 0.22% 142
2016
Q2 		$21.5M Buy
1,988,434
+227,439
+13% +$3.09M 0.15% 200
2016
Q1 		$23.9M Buy
1,760,995
+904,913
+106% +$14.1M 0.17% 187
2015
Q4 		$15.8M Buy
+856,082
New +$15.8M 0.11% 260

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eagle Asset Management's AIMT Position: Q3 2019 in Review

Eagle Asset Management sold out of Aimmune Therapeutics (AIMT) in Q3 2019, closing a stake of 1,035,885 shares — an estimated $21.6M sold.

Eagle Asset Management first reported a position in AIMT in Q4 2015 and held it in 15 quarters. The position peaked at $75.2M in Q4 2017. 146 funds tracked by Wall St. Rank hold AIMT as of Q3 2019.

  • Eagle Asset Management reported no remaining Aimmune Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Eagle Asset Management sold 1,035,885 Aimmune Therapeutics shares in Q3 2019, an estimated $21.6M.
  • Eagle Asset Management first reported a position in Aimmune Therapeutics in Q4 2015 and held it in 15 quarters.
  • Eagle Asset Management's Aimmune Therapeutics position peaked at $75.2M in Q4 2017.
  • 146 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2019.

Based on Eagle Asset Management's 13F filing for Q3 2019, filed 4 Nov 2019.